Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EBIT (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed EBIT for 6 consecutive years, with -$7.1 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 58.12% to -$7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.1 million through Dec 2025, up 50.56% year-over-year, with the annual reading at -$36.1 million for FY2025, 50.56% up from the prior year.
  • EBIT hit -$7.1 million in Q4 2025 for Bolt Biotherapeutics, up from -$7.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$7.1 million in Q4 2025 to a low of -$27.1 million in Q4 2021.
  • Historically, EBIT has averaged -$18.4 million across 5 years, with a median of -$19.1 million in 2021.
  • Biggest five-year swings in EBIT: crashed 113.87% in 2021 and later soared 59.24% in 2025.
  • Year by year, EBIT stood at -$27.1 million in 2021, then rose by 22.29% to -$21.0 million in 2022, then grew by 6.06% to -$19.8 million in 2023, then grew by 14.42% to -$16.9 million in 2024, then surged by 58.12% to -$7.1 million in 2025.
  • Business Quant data shows EBIT for BOLT at -$7.1 million in Q4 2025, -$7.7 million in Q3 2025, and -$9.2 million in Q2 2025.